MML Investors Services’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.23M Buy
15,750
+3,601
+30% +$246K ﹤0.01% 1885
2026
Q1
$785K Buy
12,149
+735
+6% +$51.8K ﹤0.01% 1930
2025
Q4
$768K Buy
11,414
+532
+5% +$35.8K ﹤0.01% 1976
2025
Q3
$798K Sell
10,882
-138
-1% -$9.17K ﹤0.01% 1884
2025
Q2
$573K Sell
11,020
-2,343
-18% -$133K ﹤0.01% 2005
2025
Q1
$853K Buy
13,363
+2,290
+21% +$133K ﹤0.01% 1687
2024
Q4
$529K Buy
11,073
+1,294
+13% +$66.4K ﹤0.01% 1882
2024
Q3
$560K Buy
9,779
+4,366
+81% +$250K ﹤0.01% 1789
2024
Q2
$283K Sell
5,413
-24
-0.4% -$1.05K ﹤0.01% 2117
2024
Q1
$221K Buy
+5,437
New +$204K ﹤0.01% 2306
2023
Q1
Sell
-3,680
Closed -$209K 2166
2022
Q4
$209K Buy
+3,680
New +$188K ﹤0.01% 2004

Other funds holding HALO

MML Investors Services's HALO Position: Q2 2026 in Review

MML Investors Services increased its Halozyme (HALO) stake by 30% in Q2 2026, buying an estimated $246K and bringing the position to 15,750 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

MML Investors Services first reported a position in HALO in Q4 2022 and has held it in 11 quarters since. 369 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • MML Investors Services held 15,750 shares of Halozyme worth $1.23M as of Q2 2026.
  • MML Investors Services bought 3,601 Halozyme shares in Q2 2026, an estimated $246K.
  • Halozyme made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #1885 holding.
  • MML Investors Services first reported a position in Halozyme in Q4 2022 and has held it in 11 quarters since.
  • 369 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.